Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-05-16

Clinical Trial Update: A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis [Phase 3]

View source ↗

Summary

A Phase 3 study comparing CT-P41 and US-licensed Prolia in postmenopausal osteoporosis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CT-P41 (denosumab)
  • Prolia (denosumab)

Snippet

Sponsor: Celltrion | Conditions: Postmenopausal Women With Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2024-05-16